Form 4: EBR Systems CEO Granted Stock Options Subject to Shareholder Approval

EBR Systems' CEO, John McCutcheon, was granted stock options to purchase 1,884,615 shares, contingent on shareholder approval at the 2025 annual meeting.

Summary

• John McCutcheon, President and CEO of EBR Systems, was granted stock options on May 21, 2025.
• The options allow him to purchase 1,884,615 shares of common stock at an exercise price of $1.04 per share.
• The grant is subject to shareholder approval at the 2025 annual meeting, as required by the Australian Securities Exchange (ASX) listing rules.
• The options vest in 1/48th equal monthly installments starting May 21, 2025, contingent upon continued employment.
• Vesting may accelerate under certain severance and change of control agreements.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to executives, which is generally viewed positively as it aligns management's interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The stock option grant aligns the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.
• The exercise price of $1.04 could be considered favorable if the stock price increases.

Risks

• Shareholder approval is not guaranteed, and the grant could be rejected.
• The value of the options depends on the future performance of the company's stock.
• The CEO's departure could impact the vesting schedule and the number of options ultimately exercised.

Future Outlook

The grant of stock options is contingent on shareholder approval at the 2025 annual meeting, and the value of the options will depend on the future performance of EBR Systems' stock.

Management Comments

• The exercise price was determined and approved by the Board of Directors on March 18, 2025, subject to approval by the Company's stockholders at the 2025 annual meeting of stockholders (including any adjournment or postponement thereof) in accordance with the Listing Rules of the Australian Securities Exchange (ASX).
• The Board of Directors approved the grant on March 18, 2025, subject to approval by the Company's stockholders at the 2025 annual meeting of stockholders (including any adjournment or postponement thereof) in accordance with the Listing Rules of the ASX.

Industry Context

Stock options are a common form of executive compensation in the technology and healthcare industries, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating executives in publicly listed companies, particularly in growth-oriented sectors like medical technology.
• The size of the grant and the vesting schedule are typical for CEO compensation packages, designed to incentivize long-term performance.
• Comparable companies in the medical device space, such as Medtronic or Boston Scientific, also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• Shareholders: Potential dilution of ownership if the options are exercised.
• Employees: May view the grant as a positive sign of the company's commitment to its leadership.
• CEO: Increased incentive to improve company performance and shareholder value.

Next Steps

• Shareholder vote on the stock option grant at the 2025 annual meeting.
• Continued monitoring of the CEO's employment status to track vesting.
• Potential exercise of the options by the CEO as they vest.

Key Dates

Keywords

stock options, EBR Systems, CEO, John McCutcheon, shareholder approval, ASX, vesting, Form 4, insider trading